Literature DB >> 33219341

Insulin-like growth factor-I predicts sinusoidal obstruction syndrome following pediatric hematopoietic stem cell transplantation.

Maria Ebbesen1, Sarah Weischendorff2, Katrine Kielsen2,3, Marte Kammersgaard2,3, Anders Juul4, Klaus Gottlob Müller2,3.   

Abstract

Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT) initiated through damage of sinusoidal endothelium and inflammation. Insulin-like growth factor-l (IGF-l) maintains and repairs endothelium and intestinal mucosa. We hypothesized that low IGF-l levels may increase the risk of inflammatory complications, such as SOS, in HSCT-patients. We prospectively measured IGF-l concentrations in 121 pediatric patients before, during, and after allogeneic HSCT. Overall, IGF-l levels were significantly reduced compared with healthy sex- and age-matched children. IGF-I levels pre-HSCT and at day 0 were inversely associated with C-reactive protein levels, hyperbilirubinemia, and number of platelet transfusions within the first 21 days post-transplant. Low levels of IGF-I before conditioning and at day of transplant were associated with increased risk of SOS diagnosed by the modified Seattle criteria (pre-HSCT: OR = 1.7 (95% CI: 1.2-2.6, p = 0.01), and the pediatric EBMT criteria (pre-HSCT: 1.7 (1.2-2.5, p = 0.009) and day 0: 1.7 (1.3-2.5, p = 0.001)/SDS decrease in IGF-1). These data suggest that IGF-I is protective against cytotoxic damage and SOS, most likely through trophic effects on endothelial cells and anti-inflammatory properties, and may prove useful as a predictive biomarker of SOS.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33219341     DOI: 10.1038/s41409-020-01127-3

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

Review 1.  Serum levels of insulin-like growth factor I and its binding proteins in health and disease.

Authors:  Anders Juul
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

2.  Influence of bacterial endotoxin on the allogenicity of human endothelial cells.

Authors:  G Eissner; G Multhoff; E Holler
Journal:  Bone Marrow Transplant       Date:  1998-06       Impact factor: 5.483

3.  Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Authors:  Paul G Richardson; Angela R Smith; Brandon M Triplett; Nancy A Kernan; Stephan A Grupp; Joseph H Antin; Leslie Lehmann; Maja Miloslavsky; Robin Hume; Alison L Hannah; Bijan Nejadnik; Robert J Soiffer
Journal:  Br J Haematol       Date:  2017-04-26       Impact factor: 6.998

4.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Authors:  Selim Corbacioglu; Simone Cesaro; Maura Faraci; Dominique Valteau-Couanet; Bernd Gruhn; Attilio Rovelli; Jaap J Boelens; Annette Hewitt; Johanna Schrum; Ansgar S Schulz; Ingo Müller; Jerry Stein; Robert Wynn; Johann Greil; Karl-Walter Sykora; Susanne Matthes-Martin; Monika Führer; Anne O'Meara; Jacek Toporski; Petr Sedlacek; Paul G Schlegel; Karoline Ehlert; Anders Fasth; Jacek Winiarski; Johan Arvidson; Christine Mauz-Körholz; Hulya Ozsahin; Andre Schrauder; Peter Bader; Joseph Massaro; Ralph D'Agostino; Margaret Hoyle; Massimo Iacobelli; Klaus-Michael Debatin; Christina Peters; Giorgio Dini
Journal:  Lancet       Date:  2012-02-23       Impact factor: 79.321

Review 5.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

6.  On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease.

Authors:  E Carreras; A Grañena; M Navasa; M Bruguera; V Marco; J Sierra; M D Tassies; J C García-Pagán; J M Martí; J Bosch
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

7.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

8.  Insulin-like growth factor 1 opposes the effects of C-reactive protein on endothelial cell activation.

Authors:  Shao-Jun Liu; Yun Zhong; Xiang-Yu You; Wei-Hua Liu; Ai-Qun Li; Shi-Ming Liu
Journal:  Mol Cell Biochem       Date:  2013-09-25       Impact factor: 3.396

9.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Authors:  Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert Soiffer; Thomas Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James Vredenburgh; Allen R Chen; Sally Arai; Georgia Vogelsang; George B McDonald; Eva C Guinan
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Authors:  Paul G Richardson; Marcie L Riches; Nancy A Kernan; Joel A Brochstein; Shin Mineishi; Amanda M Termuhlen; Sally Arai; Stephan A Grupp; Eva C Guinan; Paul L Martin; Gideon Steinbach; Amrita Krishnan; Eneida R Nemecek; Sergio Giralt; Tulio Rodriguez; Reggie Duerst; John Doyle; Joseph H Antin; Angela Smith; Leslie Lehmann; Richard Champlin; Alfred Gillio; Rajinder Bajwa; Ralph B D'Agostino; Joseph Massaro; Diane Warren; Maja Miloslavsky; Robin L Hume; Massimo Iacobelli; Bijan Nejadnik; Alison L Hannah; Robert J Soiffer
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.